171549-92-1

Basic information

• Product Name: Carbamic acid, (3-formylcyclobutyl)-, 1,1-dimethylethyl ester, trans- (9CI)
• Synonyms: Carbamic acid, (3-formylcyclobutyl)-, 1,1-dimethylethyl ester, trans- (9CI);rel-tert-butyl N-[(1r,3r)-3-formylcyclobutyl]carbamate
• CAS NO: 171549-92-1
• Molecular Formula: C10H17NO3
• Molecular Weight: 199.24688
• Product Categories: N-BOC
• Mol File: 171549-92-1.mol

Chemical Properties

• Boiling Point: 304.8±31.0 °C(Predicted)
• Appearance: /
• Density: 1.07±0.1 g/cm3(Predicted)
• PKA: 12.14±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-formylcyclobutyl)-, 1,1-dimethylethyl ester, trans- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-formylcyclobutyl)-, 1,1-dimethylethyl ester, trans- (9CI)(171549-92-1)
• EPA Substance Registry System: Carbamic acid, (3-formylcyclobutyl)-, 1,1-dimethylethyl ester, trans- (9CI)(171549-92-1)

Safety Data

• Hazardous Substances Data: 171549-92-1(Hazardous Substances Data)

Upstream product

• 167081-37-0 tert-butyl ((1r,3r)-3-(hydroxymethyl)cyclobutyl)carbamate 
• 142733-64-0 cis-3-hydroxymethyl-1-<(t-butoxycarbonyl)amino>cyclobutane 
• 142733-63-9 cis-methyl 3-<(t-butoxycarbonyl)amino>cyclobutanecarboxylate 
• 167081-37-0 trans-(3-hydroxymethyl-cyclobutyl)-carbamic acid tert-butyl ester 
• 946152-71-2 ethyl 3-{[(tert-butoxy)carbonyl]amino}cyclobutane-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

INHIBITORS OF THE MENIN-MLL INTERACTION

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

ISOXAZOLE β-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:wherein R1, R2, R3, and L, A, and Ra are defined herein.